Latest News

A same-platform, prospective comparison of 123 eyes suggests diffractive trifocal optics don't compromise standard automated perimetry outside the central 5°

Survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.

Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.

Esen Akpek, MD, weighs in on lifitegrast-perfluorohexyloctane phase 2 data and what it means for the drop's path to phase 3.

A priority review in Stargardt disease, two pivotal-trial milestones, an emerging bispecific for wet AMD, and new diagnostic guidance defined a busy August for retina.

Antibiotic injection reduced endophthalmitis risk vs topical drops after cataract surgery, meta-analysis found.

This article discusses the evolution of the body of information about Demodex blepharitis over the years, from the convening of a consensus panel to the realization that a new drug provides rapid relief to the ocular surface.

João Pedro Marques, MD, PhD, on how systematic reanalysis moved a cohort's solved rate from 59.4% to 70.1% and what it means for gene therapy eligibility

A systematic review of 21 studies found OCTA detects early diabetic retinopathy—reduced vessel density being the most consistent biomarker—but heterogeneous, unstandardized evidence isn't sufficient for routine clinical screening yet.

Two optical treatment modalities can slow pediatric myopia progression without the need for pharmacologic intervention, ie, spectacle lenses incorporating highly aspherical lenslets (HAL) and orthokeratology (ortho-k) contact lenses. Both treatments are based on the same underlying theory that peripheral retinal defocus is a growth signal for axial elongation‚ but the treatments focus on different structures of the visual system, one through a manufactured spectacle lens surface (HAL) and the other through temporary corneal reshaping (ortho-k).

The agency assigned a PDUFA target action date of April 30, 2027.